Search research articles
Contact Us
Filters
Showing results (101-110 of 164) with videos related to
Page
of 17
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 15, 2018
Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study
Christian Simon, Carmela Caballero, Vincent Gregoire, et al.
Breast Cancer Research : BCR
|
November 23, 2014
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer
Sébastien Toffoli, Isabelle Bar, Fadi Abdel-Sater, et al.
Lancet (London, England)
|
December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
European Urology
|
June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2011
Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer
Peter P Grimminger, Peter Danenberg, Kathrin Dellas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
Charles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinoma
Iman El-Hariry, Thomas Powles, Mike R Lau, et al.
Clinical Genitourinary Cancer
|
June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
Petri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 9, 2011
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study
Vincent Gregoire, Marc Hamoir, Changhu Chen, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 164) with videos related to
Sort By:
Page
of 17
European Journal of Cancer (Oxford, England : 1990)
|
September 15, 2018
Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 'Best of' and 24954 'larynx preservation' study
Christian Simon, Carmela Caballero, Vincent Gregoire, et al.
Breast Cancer Research : BCR
|
November 23, 2014
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer
Sébastien Toffoli, Isabelle Bar, Fadi Abdel-Sater, et al.
Lancet (London, England)
|
December 5, 2018
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, et al.
European Urology
|
June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2011
Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer
Peter P Grimminger, Peter Danenberg, Kathrin Dellas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
Charles J Ryan, Mark Rosenthal, Siobhan Ng, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinoma
Iman El-Hariry, Thomas Powles, Mike R Lau, et al.
Clinical Genitourinary Cancer
|
June 12, 2016
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
Petri Bono, Stephane Oudard, Istvan Bodrogi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 9, 2011
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study
Vincent Gregoire, Marc Hamoir, Changhu Chen, et al.
Page
of 17